OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO™ and KEYTRUDA® Plus Chemotherapy

Jun 09, 2020 9:00am EDT

OncoSec to Present at Virtual Summer Investor Summit

Jun 04, 2020 9:00am EDT

OncoSec Strengthens IP Portfolio with Three New Patents Covering TAVO™ and Its Electroporation Gene Delivery System

May 27, 2020 9:00am EDT

OncoSec to Present Two Late-Breaking Pre-Clinical Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II

May 21, 2020 9:00am EDT

OncoSec Partners with the Melanoma Research Foundation to Host Live Panel Discussion during Melanoma Awareness Month

May 14, 2020 9:00am EDT

OncoSec’s TAVO™ Receives ATMP Certification from European Medicines Agency to Support Marketing Authorization Application in Metastatic Melanoma

May 13, 2020 9:18am EDT

OncoSec’s TAVO™ in Combination with KEYTRUDA® Demonstrated 41% Overall Response Rate and 36% Complete Response in a Late-Stage Metastatic Melanoma Study Featured in ‘Clinical Cancer Research’

May 06, 2020 9:00am EDT

OncoSec Presents Pre-Clinical Data from Its Visceral Lesion Applicator (VLA) and APOLLO Feasibility Study Demonstrating TAVO™ Can Be Safely Delivered and Electroporated in Liver at the Online Society of Interventional Radiology Annual Meeting

Apr 21, 2020 9:00am EDT

OncoSec Appoints Renowned Oncologist and Immunologist, Herbert Kim Lyerly, M.D., Duke University, to its Board of Directors

Apr 20, 2020 9:00am EDT

OncoSec Collaborates with Providence Cancer Institute to Conduct First-in-Human Trial of OncoSec’s CORVax12, an Investigational Vaccine to Prevent COVID-19, Combining an Enhanced "Spike" DNA Sequence and TAVO™

Apr 06, 2020 9:00am EDT